Hepatitis SurveillanceViral Hepatitis Surveillance Program, 1993
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
Figure
1. Serologic Tests to Diagnose Hepatitis, 1983-1993
|
|
|
Figure
2. Trends in Selected Risk Factors for Patients Reported with
Hepatitis A, by Mutually Exclusive Groups, United States, 1983-1993
|
|
|
Figure
3. Trends in Selected Risk Factors for Patients Reported with
Hepatitis B by Mutually Exclusive Groups, Males, Selected States,
1983-1993
|
|
|
Figure
4. Trends in Selected Risk Factors for Patients Reported with
Hepatitis B by Mutually Exclusive Groups, Females, Selected States,
1983-1993
|
|
| Figure 5. Trends in Selected Risk Factors for Patients Reported with Hepatitis C/NANB, by Mutually Exclusive Groups, Selected States, 1983-1993 |
| The total numbers of cases reported to the
Viral Hepatitis Surveillance Program (VHSP) are shown in
Table 1A. Approximately 36% of hepatitis A
cases, 26% of hepatitis B cases, and 18% of NANB hepatitis cases
reported to the NNDSS in 1993 were also reported to the VHSP. These
percentages reflect a substantial decline in reporting to the VHSP.
Reporting to the VHSP remains inconsistent among states, with
increasing numbers of states reporting fewer of their NNDSS cases to
the VHSP than in previous years (Table 1B). In
1987, six states reported to VHSP less than 15% of their NNDSS cases;
in 1993, this trend increased to 12 states.
These differences in proportions of cases are partly due to the fact that VHSP excludes cases that do not meet the case definition (VHSP eliminated 15% of reported cases as non-cases in 1993). In addition, because of strict adherence to the case definition, VHSP classified a larger proportion of reported cases as nonspecific hepatitis: 15% of cases were classified as hepatitis unspecified by the VHSP during 1993 compared with 1.5% of cases reported to NNDSS. Beginning with data collected in 1995, hepatitis cases that have type unspecified are no longer requested or printed in the MMWR. The VHSP excludes reported cases that do not meet the case definition for acute viral hepatitis (see "Case Definition" section), including cases that seem to be due to chronic infections. Some responses to the VHSP questionnaires are incomplete, and the information is insufficient to verify the case as an acute infection, or to confirm the serologic type of hepatitis, even though partial testing may have been done. Cases may also be reported too late to be included in the analysis. The latest date for submitting case reports to the VHSP for the calendar year is March 31 of the following year. Serologic testing for the diagnosis of hepatitis, beginning with hepatitis B surface antigen (HBsAg) in 1972, immunoglobulin-M antibody to hepatitis A virus (IgM anti-HAV) in 1981, and IgM antibody to hepatitis B core antigen (IgM anti-HBc) in 1984, has been critical in distinguishing the types of viral hepatitis. Serologic testing for any marker using one or more tests has increased from 60% in 1983 to 94% in 1993 (Figure 1). By 1993, only 6% of reported cases were diagnosed on the basis of the HBsAg test alone. However, there has been a decline in the number of cases reported in which testing for both hepatitis A and hepatitis B was done. In 1989, 76% of physicians reported using tests for both types (the highest percentage reached); this declined to 70% in 1990, 68% in 1991, 63% in 1992, and to 55% in 1993. At the same time, the number of cases reported in which testing only for hepatitis A was done increased over this period, from 15% in 1989 to 28% in 1993. The reliance on testing for hepatitis A alone for these cases may be related to the higher incidence of hepatitis A in community-wide outbreaks since 1989. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Case DefinitionEpidemiologic data about reported cases of acute viral hepatitis are essential for defining the groups at risk and for monitoring changes in such groups. Since new disease acquisition is the event of interest, chronic infections should not be reported. In 1990 the VHSP updated the case definition for acute viral hepatitis to include IgM anti-HBc for improved diagnosis of acute hepatitis B, to clarify the reporting of NANB hepatitis, and to include delta hepatitis as a separate diagnostic category. The clinical criteria remain the same: an acute case must include an illness with discrete date of onset, and jaundice or elevated serum aminotransferase levels greater than 2.5 times the upper limit of normal. The serologic criteria used to distinguish the different types of hepatitis were as follows: hepatitis A is defined as IgM anti-HAV-positive (regardless of HBsAg status); hepatitis B as IgM anti-HBc-positive (if done) or HBsAg-positive and IgM anti-HAV-negative (if done); and NANB hepatitis as IgM anti-HAV-negative, and IgM anti-HBc-negative (if done) or HBsAg-negative. Although by 1993 only 55% of reported cases were tested for both hepatitis A and B, 87% had sufficient serologic testing to designate a specific type. Only those patients with a specific serologic diagnosis are included in the following analyses. Cases are excluded if they do not satisfy the criteria for acute viral hepatitis. Among serologically confirmed cases in 1993, 6% of hepatitis A cases, 13% of hepatitis B cases, and 9% of NANB hepatitis cases were excluded because they failed to meet the case criteria. Compared with hepatitis B patients who fulfilled the criteria for acute hepatitis, more persons with hepatitis B who were asymptomatic or had no date of onset were <14 years of age, were Asian/Pacific Islander, were dialysis patients, or had histories of blood transfusions or surgery. Except for age, NANB hepatitis patients not meeting the case definition showed a similar pattern. Compared with NANB hepatitis patients who fulfilled the criteria for acute hepatitis, more persons with NANB hepatitis who were asymptomatic or had no date of onset were >40 years of age, were patients undergoing dialysis, or had histories of surgery. This pattern, as well as that for hepatitis B, is consistent with that for the earlier years. For both hepatitis B and NANB hepatitis, these findings suggest that these persons may have been routinely screened for HBsAg or for antibody to the hepatitis C virus (anti-HCV), and found to be positive without any evidence of acute illness. Hepatitis A and B coinfections were examined in the 1993 data, and constituted approximately 1% of cases meeting the case definition. These cases displayed no specific clustering or associations with geographic or demographic factors. For purposes of risk factor analysis, these cases were counted twice, and included as hepatitis A cases and hepatitis B cases. |
Demographic Characteristics
From 1992 to 1993, the number of hepatitis A cases among patients 20-39 years of age decreased 10%; hepatitis B cases, 21%; and NANB hepatitis cases, 19%. Demographic factors for all types showed patterns consistent with those of previous years (Table 2).
In 1989, Hispanic patients accounted for 9%
of reported hepatitis A cases. While this percentage increased to 12%
by 1993, the absolute number of Hispanic cases declined, as was true
for other racial/ethnic groups. When the percentages of Hispanic cases
were examined for both old reporting forms and newly revised forms for
the 1990 data, there was no evidence that the coding of ethnicity
separately from race affected reporting of such cases. Analysis of Risk Factor DataThe analysis of epidemiologic data for 1993 took into consideration the changes in both incidence and reporting practices. Reporting was analyzed by groups of states to determine if significant biases existed in the data when reports from all participating states were included for analysis. Criteria for good reporting states ("core" states) included adequate serologic testing of reported cases (at least 80% of reported cases tested for IgM anti-HAV or HBsAg), and reporting to the VHSP of a high proportion of cases reported to NNDSS (at least 50% of total cases reported to NNDSS also reported to VHSP). In addition, core states were further subdivided into those with rates above the national average for each type, and those with rates below the national average, and comparisons were made between these subgroups. Trends in these core states were then compared to trends in the remaining states for evidence of consistency and potential bias. For hepatitis A, analysis of the core group of states showed that trends were very similar between the core states and all reporting states, and between the high-rate and low-rate subgroups. In the trend analyses that follow, hepatitis A risk factors were based on reported cases from all reporting states, and trends were analyzed by using absolute numbers of cases. For hepatitis B and C/NANB, a core group of 15 states were selected using the same reporting criteria and high levels of serologic testing for HBV during 1983-1993. These states accounted for approximately 30% of all cases of hepatitis B reported to the VHSP in this period. For hepatitis B and C/NANB hepatitis, artifactual changes in reporting levels resulted in significant differences between the trends for all VHSP states and the trends in the core states, although there were no differences between high- and low-incidence states. For hepatitis B and hepatitis C/NANB hepatitis, trends in risk factors were analyzed by using absolute numbers of cases from the core states only. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Epidemiologic Characteristics
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hepatitis A
Since hepatitis A has an average incubation period of 30 days and is transmitted by the fecal-oral route, the characteristics reported by persons with hepatitis A as having occurred in the 6 weeks to 6 months prior to illness (Table 3) are generally not applicable to transmission of this virus.(2) Although homosexual men are considered at increased risk of acquiring hepatitis A,(3) the frequency with which homosexual activity was reported by persons with hepatitis A (3.6%) may be understated, since only 46% of the patients were asked the question in 1993. However, this percentage has increased in recent years. The frequency with which injection drug use was reported by patients with hepatitis A may be more reliable than in the past, since over 70% of patients with hepatitis A answered this question in 1993. These improvements lend greater validity to these data than in previous years. Of patients reporting personal contact with a hepatitis A patient, 10% reported sexual, 45% reported household, and 45% reported other contact. Of those reporting other than sexual or nonsexual household contact, none had reported day-care-related exposures, but 8% reported being a part of a suspected outbreak. To better define patterns of hepatitis A virus transmission, patients who reported more than one potential source of infection were assigned to only one group on the basis of their most probable source. These mutually exclusive groups are shown in Table 4. Contact with another person with hepatitis A was the risk factor most frequently cited. Association with a day-care center and international travel were the two risk factors next in importance.
International travel was reported in 6% of hepatitis A cases in 1993. South and Central America were the locations visited most frequently (67% of travel-related cases in 1993). Destinations in Asia and the South Pacific were visited next most often (10% of cases in 1993). The duration of stay was 1-3 days in 17% of cases with international travel as a risk factor, 4-7 days in 15%, and more than 7 days in 68%. Among patients reporting short stays (1-3 days), over 90% reported visits to South/Central America. Race and ethnicity were examined among hepatitis A patients with international travel as a risk factor. Hispanic patients accounted for 47%, non-Hispanic whites accounted for 43%, and Asian/Pacific Islanders for 8% of cases. Non-Hispanic blacks accounted for less than 2% of travel-related cases in 1993. There was an association between race and location visited: 92% of Hispanic patients with travel-related hepatitis A visited South/Central America, while 75% of non-Hispanics did so. Among Asian/Pacific Islander patients, 85% visited Asian/South Pacific destinations, while 0% to 7% of other races or ethnic groups visited these locations. Because the total number of hepatitis A cases reported has changed over the years, the absolute numbers of cases for each risk factor show more accurately the trends over time for hepatitis A. The numbers of cases associated with personal contact with another hepatitis A patient during 1983-1993 have exhibited the greatest variation (Figure 2), with an increase of over 100% occurring from 1983 to 1989, followed by a comparable decrease from 1989 to 1993. Day-care-related cases increased more slowly during this period, but peaked in 1989 also, followed by a drop of 47%. The numbers of cases attributable to drug use increased steadily between 1983 and 1989, and declined rapidly to their present low level. Cases related to homosexual activity remained at low levels from 1983 through 1987. By 1989, however, there was a 3.6-fold increase in cases of hepatitis A among homosexual men, and outbreaks of hepatitis A in this population subgroup were reported. Cases among homosexual men have remained at higher levels through 1993. Foreign travel and foodborne outbreak-associated cases peaked in 1988 and declined overall since then. Jaundice characterized an average of 85% of the reported hepatitis A cases in 1993. Although this frequency was similar across age-groups, jaundice and other symptoms are uncommon among young children infected with hepatitis A virus. Thus, reported cases substantially underestimate the infection burden among the youngest age-group. The rate of hospitalization of patients with hepatitis A has remained steady in 1993, and continues to increase with increasing age. The case-fatality rate for hepatitis A patients also increased with age, and showed a slight increase with time as well for those aged 15 and over in 1993. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hepatitis B
Seventy-two percent of the persons with hepatitis B were asked about potential risk factors commonly associated with hepatitis A that occurred within the 2 to 6 weeks prior to illness. Although these factors are generally not associated with the transmission of HBV because the incubation period is too short, health-care workers interviewing patients with hepatitis are encouraged to obtain from each patient information on all types of risk factors, both to detect newly emerging problems (as occurred with injection drug use and hepatitis A) and to ensure a complete exposure history when cases are serologically classified. Events or conditions reported within the 6 months prior to hepatitis B illness -- such as history of dental work, surgery, acupuncture, tattooing, or other percutaneous exposures -- are not considered likely sources of sporadic infection, but are primarily useful in identifying clusters of cases at the local level. Of three patients reported with acute hepatitis B and evidence of having responded to the hepatitis B vaccine, all three were also reported to have coinfections with acute hepatitis A. After follow-up with the reporting health department, none of these cases were found to be true candidates for breakthrough infections. Persons who reported multiple risk factors for hepatitis B were assigned to mutually exclusive groups(2,4-6) (Table 5). As a percentage of all cases, being heterosexually active with multiple partners has replaced injection drug use as the predominant risk factor for acquisition of hepatitis B. Personal contact with another hepatitis B patient was the third most common risk factor. Of personal contacts in 1993, 68% were sexual, and 17% were nonsexual household contacts. The remaining 15% of personal contacts, classified as "other", are unclear as to specific sources because information was insufficient to determine how transmission occurred. Employment in the medical or dental field, blood transfusions, and dialysis accounted for less than 5% of cases. For those patients employed in a medical, dental or other field involving contact with human blood, 23% reported frequent blood contact in 1993, down from 36% in 1992.
To ensure that possible biases owing to artifactual decreases in reporting were minimized, the analysis of trends in hepatitis B risk factors for 1983 to 1993 was restricted to the absolute numbers of cases reported in the core states only. For these states during 1989-1993, decreases occurred in the numbers of cases attributed to injection drug use (an 83% decrease), personal contact with a hepatitis B patient (73% decrease), and multiple sexual partners (35% decrease). The trends in risk factors associated with hepatitis B in the core states, among men and women separately, are shown in Figures 3 and 4. Among men, injection drug use has shown the largest change from 1983 to 1993. After an increase of 116% from 1983 to 1989, the numbers of cases among men attributed to injection drug use decreased by 85% (Figure 3). Safer needle-using practices, or changes in the types of drugs used (injection to noninjection) are possible reasons for this reduction. The numbers of cases among men attributable to personal contact with another hepatitis B patient has been more stable, showing a gradual decline from 1989 to 1993. For these male patients, 52% to 67% of contacts were sexual, while 13% to 20% were household contacts. Homosexual activity, the second most commonly reported risk factor, declined to its lowest level in 1993. Declines in the other reported risk factors -- health-care employment and blood transfusion -- continued through 1993. Risk factors for women with hepatitis B displayed some of the same trends presented for men, with injection drug use as a risk factor increasing from1983 to a peak in 1989 (Figure 4), followed by a drop to pre-1983 levels. However, among women, contact with another hepatitis B patient increased more dramatically than among men and since 1990, was reported with a higher frequency than injection drug use. As with men, the majority of contacts associated with such cases have been sexual, reaching 72% in 1993, while only 11% have been household contacts. The decrease in the percentage of female patients reporting medical and dental employment as a risk factor during 1983-1993 has been more pronounced than that for men. This decline is most probably attributable to immunization of health-care workers with hepatitis B vaccine. The percentage of cases attributable to blood transfusions has remained at low levels since 1988. The same trends in both men and women have been observed in the Sentinel Counties study.(19) Jaundice as a clinical characteristic of hepatitis B is a common symptom in patients over 10 years of age (Table 5); 82% of all patients were reported with jaundice, regardless of age. As with hepatitis A, jaundice and other symptoms were notably less frequent for young children, suggesting more extensive underrepresentation of this age-group among reported cases. Overall hospitalization rates remained stable, showing little change since 1988, but the rates of hospitalization for patients 40 years old and older dropped slowly but steadily, from 50% in 1985 to 36% in 1993. Death as a result of hepatitis B was reported in approximately 1% of patients in 1993. Nationwide, the incidence of hepatitis B increased by 67% from 1978 to 1985 and then declined to its lowest incidence since 1974. Since its original licensing in 1981, hepatitis B vaccine has been used in increasing quantities each year. However, the role of the vaccine in the decline of the incidence of hepatitis B varies across risk groups. From 1985 to 1989, hepatitis B among homosexual men declined more rapidly than among other risk groups, not because of vaccine use but because of behavioral changes resulting from awareness of acquired immunodeficiency syndrome (AIDS).(7) Hepatitis B also declined among health-care workers during this period, who were the largest users of hepatitis B vaccine. From 1989 to 1993, hepatitis B among injection drug users declined by 46% despite the low levels of vaccine usage in this risk group. Hepatitis B among heterosexuals decreased during this period also, possibly due to wider use of vaccine. Vaccination programs and vaccine usage have been focused primarily on three risk groups: health-care workers who are exposed to blood, staff and residents of institutions for the developmentally disabled, and staff and patients in hemodialysis units.(9) For health-care and public safety workers, the Department of Labor in 1991 issued regulations that require employers to offer hepatitis B vaccine to persons at occupational risk of infection. However, the ability to immunize the groups that account for most of the HBV infections is severely limited for several reasons: the failure both of health-care providers and of the target populations to recognize the specific groups at high risk for infection; the difficulty in identifying persons with these high-risk behaviors before they become infected; and the difficulties in reaching these groups for the delivery of vaccine and at the appropriate time for vaccination.(7) Adults in general, and groups such as injecting drug users in particular, are extremely difficult to access for delivery of vaccine.(11) In addition, once persons begin the lifestyles associated with a high-risk group, they may become infected before vaccine can be given. Thus, the major obstacles to reducing the incidence of HBV infection in the United States have been the difficulties in identifying persons before they become infected and vaccinating them promptly. To overcome these problems, the Immunization Practices Advisory Committee recommended in 1991 a program of routine vaccination of all infants.(9) In 1995 the same committee recommended the expansion of this program to cover 1) vaccination of all unvaccinated children aged <11 years who are Pacific Islanders or who reside in households of first-generation immigrants from countries where HBV is of high or intermediate endemicity; and 2) vaccination of all 11- to 12-year-old children who have not previously received hepatitis B vaccine.(9) Hepatitis C / NonA, NonB Hepatitis
The behaviors commonly associated with hepatitis A that were reported by persons with hepatitis C/NANB to have occurred within 6 weeks of illness are generally not applicable to the transmission of hepatitis C/NANB (Table 3). Since transmission of NANB hepatitis by the fecal-oral route has not been demonstrated in this country, reporting an association with a foodborne or a waterborne outbreak represents misclassification of the source. As with hepatitis B, potential exposures associated with dental work, surgery, acupuncture, tattooing, and other percutaneous procedures are not judged to be probable sources of sporadic infection.(12) Hepatitis C/NANB patients with no known source of infection reported these exposures at rates no different from those of the general population. Based on assignment to mutually exclusive categories, persons with hepatitis C/NANB reported injection drug use most frequently, accounting for 23% of cases during 1993 (Table 6). Blood transfusion accounted for 2% of cases, declining from 6% in 1990; contact with another infected person accounted for 5%, and health-care employment for 4%. Of those patients reporting health-care employment, the percentage reporting frequent (several times weekly) blood contact dropped over 1990 to 1993. Fifty-seven percent of patients employed in health-care reported frequent blood contact in 1990. By 1993, the percentage dropped to 17%. Patients classified as having multiple (2 or more) sex partners as their most likely source of infection accounted for 7% of the patients with hepatitis C/NANB; in a case-control study, this risk factor was associated with acquiring disease.(12) Overall, 58% of persons reported no known source for their infection. This percentage varied by age, with > 70% of persons younger than 15 years old or 40 years old and older reporting no known source for their infection, compared with 50% for persons 15-39 years of age. Among persons less than 15, 13.6% had a history of blood transfusion. Among persons 15 to 39 years of age, injection drug use was reported by 28% of all cases during 1993, unchanged from 1992 (Table 6). Ten percent reported multiple sex partners, 7% reported contact with another infected person, 4% reported health-care employment, and 1% reported blood transfusions. Of reported contacts with another infected person, an average of 59% were sexual contacts, 16% were household nonsexual contacts, and 25% were other (unspecified) types of contact. In prior years, persons 40 years old and older reported a history of blood transfusion most frequently among their risk factors (in 1990, 16%), but this percentage declined substantially to 4% by 1993. Injection drug use is now the most frequent risk factor for this age-group (Table 6). Because total numbers of cases of hepatitis C/NANB have declined, trends in the distribution of risk factors are more accurately reflected by trends in the absolute numbers of cases attributed to each factor. In the core states, hepatitis C/NANB cases attributable to drug use have declined rapidly since 1988, showing a more than 62% decrease (Figure 5). A similar decrease of over 50% was seen in the Sentinel Counties Study.(14) The numbers of hepatitis C/NANB cases attributable to blood transfusions have decreased even more dramatically, dropping by 94% from 1985 to 1993. The significant decline in transfusion-associated cases, which began in the mid-1980s, resulted from a series of events: changes in the blood donor population caused by self-exclusion of high-risk donors, as part of efforts to prevent HIV infection;(15,16) the introduction of screening blood donors for alanine aminotranferase and anti-HBc as surrogate markers for hepatitis C/NANB in 1986 and 1987; and use of first- and second-generation anti-HCV markers for screening donors in 1990 to the present. Jaundice was reported as a clinical symptom in 67% of reported hepatitis C/NANB patients in 1993 (Table 6). Hospitalization and case-fatality rates were higher in hepatitis C/NANB patients than in patients with hepatitis A or B. Those 40 years old and older experienced the highest rates. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Percentage of Patients By Age (years) | ||||
|---|---|---|---|---|
| Epidemiologic Characteristics for Prior 6 Months by Mutually Exclusive Groups* | Total N = 856+ |
<1-14 N = 30 |
15-39 N = 557 |
40+ N = 260 |
| Blood transfusion | 2.3 | 13.6 | 0.9 | 4.3 |
| Injection Drug use | 22.6 | 0.0 | 28.4 | 12.0 |
| Employed in medical/dental field | 3.9 | 0.0 | 3.8 | 4.6 |
| Hemodialyis | 0.7 | 0.0 | 0.2 | 1.9 |
| Personal contact with hepatitis C/NANB patient | 5.3 | 6.7 | 7.2 | 1.2 |
| Multiple sex partners | 7.4 | 0.0 | 9.9 | 3.1 |
| Unknown | 57.8 | 79.7 | 49.6 | 72.9 |
| Clinical Characteristics | ||||
| Jaundice | 66.9 | 75.0 | 69.6 | 60.1 |
| Hospitalized for hepatitis | 32.9 | 32.1 | 28.8 | 41.7 |
| Death as a result of hepatitis | 1.9 | 0.0 | 0.8 | 4.5 |
| * In decreasing order of
exclusion. + Number includes age unknown. Source: Viral Hepatitis Surveillance Program |
||||
The majority of NANB hepatitis cases in this country are caused by the
hepatitis C virus;(14)
the remainder are probably due mostly to other bloodborne hepatitis agents.
Outbreaks of hepatitis E, an enterically transmitted form of hepatitis NANB,
have been reported in rural Mexican villages (17), as well as in Asia and
North and West Africa,(18)
but no outbreaks have been reported in this country.(19)
In the United States and other countries where hepatitis E outbreaks have
not been documented to occur, rare hepatitis E cases have been reported,
primarily among travelers returning from HEVendemic regions.(20)
No secondary transmission to family members or other persons in association
with these cases has been reported. In the United States, hepatitis E cases
have been reported with no history of travel to HEVendemic areas; however,
the mode of HEV transmission for these cases has not been determined.
Viral hepatitis surveillance in 1993 revealed several important changes from
earlier years. First, total cases reported to the VHSP declined more than
51% from 1990 to 1993, as a result of both real declines in the incidence of
hepatitis A and B, and a number of states that previously reported now
submitting fewer or none of their cases to the VHSP. Second, the use of
serologic tests to diagnose the specific type of hepatitis has declined,
with fewer reported cases being diagnosed on the basis of tests for both
hepatitis A and B. Third, analysis of trends in risk factors for the
acquisition of the different types of hepatitis indicated that injection
drug use has declined dramatically for hepatitis A, B, and hepatitis C/NANB.
Finally, more widespread use of hepatitis B vaccine may be having an effect
on the number of hepatitis B cases acquired by heterosexual activity.
Underreporting and incomplete case ascertainment are potential sources of inaccuracy and may lead to inaccurate conclusions from surveillance data, particularly in the relative frequencies of reported risk factors.(21) Since case ascertainment is dependent on the availability of sensitive and specific serologic tests, estimates of the frequency of disease types such as hepatitis C/NANB, for which there are no markers of acute disease, are likely to be the least reliable. The analysis of VHSP data on biases in the reporting of hepatitis B and hepatitis C/NANB showed that consistent reporting practices are critical for the accurate interpretation of surveillance data in this country. In addition, national data are averaged over many regions with potentially large geographic differences in risk factors and disease incidence. Therefore, the overall frequencies of various risk factors may not reflect their importance in smaller geographic areas.
Despite the drawbacks associated with a passive surveillance system, the data collected through the VHSP are essential for monitoring trends in the epidemiologic characteristics of the various types of viral hepatitis. These data are also valuable for monitoring the impact of prevention programs on disease in various high-risk groups, such as those targeted to receive hepatitis B vaccine. The recently recommended program for the universal immunization of infants for hepatitis B was the direct result of the analysis of surveillance data, and provides evidence that contributors to the VHSP have made a positive impact on public health.
Many dedicated public health practitioners, local medical authorities, and public health communities contribute to this surveillance system through their timely diagnosis and reporting of hepatitis cases. We are grateful for their continued participation and encourage them to continue to improve their use of serologic testing, their consistency in reporting, and the quality of the information they provide.
Figure 1. Serologic Tests to Diagnose Hepatitis, 1983-1993 |
Figure 2: Trends in Selected Risk Factors for Patients Reported with Hepatitis A, by Mutually Exclusive Groups, United States, 1983-1993 |

Figure 3. Trends in Selected Risk Factors for Patients Reported with Hepatitis B by Mutually Exclusive Groups, Males, Selected States, 1983-1993 |
Figure 4. Trends in Selected Risk Factors for Patients Reported with Hepatitis B by Mutually Exclusive Groups, Females, Selected States, 1983-1993 |
Figure 5. Trends in Selected Risk Factors for Patients Reported with Hepatitis C/NANB, by Mutually Exclusive Groups, Selected States, 1983-1993 |
1. McQuillan GM, Townsend TR, Fields HA, et al. Seroepidemiology of hepatitis B virus infection in the United States. Am J Med 1989;87(suppl 3A):5S-10S.
2. Francis DP, Maynard JE. The transmission and outcome of hepatitis A, B, and nonA, nonB: a review. Epidemiol Rev 1979;1:1731.
3. Corey L, Holmes KK. Sexual transmission of hepatitis A in homosexual menincidence and mechanism. N Engl J Med 1980;302:4358.
4. Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982;115:2639.
5. Hadler SC, Doto IL, Maynard JE, et al. Occupational risk of hepatitis B infection in hospital workers. J Infect Control 1985;6:2431.
6. Schreeder MT, Thompson SE, Hadler SC, et al. Hepatitis B in homosexual men: prevalence of infection and factors related to transmission. J Infect Dis l982;146:715.
7. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. JAMA 1990;263:1218-22.
8. Immunization Practices Advisory Committee. Recommendations for protection against viral hepatitis. MMWR 1985;34:31324,32935.
9. Immunization Practices Advisory Committee. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40:1-25.
10. Immunization Practices Advisory Committee. Update: recommendations to prevent hepatitis B virus transmission -- United States. MMWR 1995;44:574-5.
11. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
12. Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201-5.
13. Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute nonA, nonB hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990;264:2231-5.
14. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infectious Agents and Disease 1993;2:155-66.
15. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of nonA, nonB hepatitis in recipients. N Engl J Med 1981;304:98994.
16. Koziol DE, Holland PV, Alling DW, et al. Antibody to hepatitis B core antigen as a paradoxical marker for nonA, nonB hepatitis agents in donated blood. Ann Intern Med 1986;104:48895.
17. CDC. Enterically transmitted nonA, nonB hepatitis Mexico. MMWR 1987;36:597602.
18. Bellabbes EH, Bourguermouh A, Benatallah A, Illoul G. Epidemic non-A, non-B hepatitis in Algeria: strong evidence for its spreading by water. J Med Virol 1985;16:257-63.
19. Mast EJ, Alter MJ. Epidemiology of viral hepatitis: an overview. Seminars in Virology 1993;4:273-83.
20. DeCock KM, Bradley DW, Sandford NG, Govindarajan S, Maynard JE, Redeker AG. Epidemic non-A, non-B hepatitis in patients from Pakistan. Ann Intern Med 1987;106:227-30.
21. Alter MJ, Mares A, Hadler SC, Maynard JE. The effect of underreporting on the apparent incidence and epidemiology of acute viral hepatitis. Am J Epidemiol 1987;125:1339.